Overview

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

Status:
Recruiting

Trial end date:
2024-08-30

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).

Phase:

Phase 4

Details

Lead Sponsor:

Janssen-Cilag Ltd.

Treatments:

Esketamine